• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Effect of Subcutaneous Administration of Denosumab in Postmenopausal Osteoporosis

    Prasenjit Das, Sunil Goenka, Rajesh Kumar Sharma

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2529-2536

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Introduction:  Postmenopausal  osteoporosis  is  a  major  health  problem  in  Indian  women  as  it  increases  chances  of  both  vertebral  and  non-vertebral  fractures. The  benefits  of  the  standard  treatment  regimen  for  prevention  of  postmenopausal  osteoporosis  are  not  encouraging. Denosumab, in  various  international  studies  is  found  as  an  effective  treatment  modality  for  prevention  of  postmenopausal  osteoporosis. However, there  is  scarcity  of  data  of  Indian  postmenopausal  women. Therefore, present  study  is  an  attempt  to  observe  the  treatment  effect  of  denosumab  for  prevention  of  postmenopausal  osteoporosis.  Objective: To  observe  the  treatment  effect  of  denosumab  in  patients  suffering  from  postmenopausal  osteoporosis  in  terms  of   bone  mineral  density(BMD).
Methods:  This  randomized  control  study  was  done  in 62  randomly  selected  patients  with  postmenopausal  osteoporosis  at  SMS  Hospital, Jaipur. After  administering denosumab (60 mg  every  6 months), we  measured  lumbar  spine, total  hip  and  distal  radius  BMD  at  6  and  12  months.
Results: At  6  months, lumbar  spine  BMD  increased  more  in  denosumab  group(0.29±0.17, P˂0.001) compared  to  control  group(0±0.29, P˂0.001)  and  at  the  end  of  12  months also, lumbar spine  BMD  increased  more in  denosumab  group(0.56±0.24, P˂0.001) compared  to  control  group(-0.03±0.41, P˂0.001). Similarly, at  6 months, total  hip  BMD  increased  more  in  denosumab  group(0.38±0.23, P˂0.001)  compared  to  control  group(-0.08±0.22, P˂0.001) and  at  the  end  of  12  months, total  hip BMD  increased  more in  denosumab  group(0.82±0.3, P˂0.001) compared to  control  group(-0.1±0.36, P˂0001). At  6  months, distal  radius  BMD  increased  more  in  denosumab  group(0.27±0.25)  compared  to  control  group(0.00±0.37)  and  at  12  months, distal  radius  BMD  increased  more  in  denosumab  group(0.58±0.34)  compared  to  control  group(-0.04±0.43).
Conclusions: Denosumab  is  effective  to  treat  postmenopausal  osteoporosis   and  it  is  more  effective   at  hip  than  at  lumbar  spine  and  radius. To  conclude  further  treatment  is  needed  as  sequential  therapy  because  on  stopping  the treatment  BMD  again  start  receding  over  the  period.
Keywords:
  • PDF (392 K)
  • XML
(2022). Effect of Subcutaneous Administration of Denosumab in Postmenopausal Osteoporosis. European Journal of Molecular & Clinical Medicine, 9(3), 2529-2536.
Prasenjit Das, Sunil Goenka, Rajesh Kumar Sharma. "Effect of Subcutaneous Administration of Denosumab in Postmenopausal Osteoporosis". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 2529-2536.
(2022). 'Effect of Subcutaneous Administration of Denosumab in Postmenopausal Osteoporosis', European Journal of Molecular & Clinical Medicine, 9(3), pp. 2529-2536.
Effect of Subcutaneous Administration of Denosumab in Postmenopausal Osteoporosis. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 2529-2536.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 78
  • PDF Download: 163
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus